Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Edaravone in ALS
NCT04176224Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point at Day 2, Maximum Plasma Concentration at Day 2 and 10 more. Started Apr 2019; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04176224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176224.